期刊文献+

Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer 被引量:8

Divergent expression of bacterial wall sensing toll-like receptors 2 and 4 in colorectal cancer
下载PDF
导出
摘要 To characterize the expression of toll-like receptors (TLR) 2 and 4 in colorectal cancer (CRC) and in normal colorectal mucosa. METHODSWe analysed tissue samples from a prospective series of 118 unselected surgically treated patients with CRC. Sections from formalin fixed, paraffin embedded specimens were analysed for TLR2 and TLR4 expression by immunohistochemistry. Two independent assessors evaluated separately expression at the normal mucosa, at the invasive front and the bulk of the carcinoma, and in the lymph node metastases when present. Expression levels in different locations were compared and their associations with clinicopathological features including TNM-stage and the grade of the tumour and 5-year follow-up observations were analysed. RESULTSNormal colorectal epithelium showed a gradient of expression of both TLR2 and TLR4 with low levels in the crypt bases and high levels in the surface. In CRC, expression of both TLRs was present in all cases and in the major proportion of tumour cells. Compared to normal epithelium, TLR4 expression was significantly weaker but TLR2 expression stronger in carcinoma cells. Weak TLR4 expression in the invasive front was associated with distant metastases and worse cancer-specific survival at 5 years. In tumours of the proximal colon the cancer-specific survival at 5 years was 36.9% better with strong TLR4 expression as compared with those with weak expression (P = 0.044). In contrast, TLR2 expression levels were not associated with prognosis. Tumour cells in the lymph node metastases showed higher TLR4 expression and lower TLR2 expression than cells in primary tumours. CONCLUSIONTumour cells in CRC show downregulation of TLR4 and upregulation of TLR2. Low expression of TLR4 in the invasive front predicts poor prognosis and metastatic disease. AIM To characterize the expression of toll-like receptors(TLR) 2 and 4 in colorectal cancer(CRC) and in normal colorectal mucosa.METHODS We analysed tissue samples from a prospective series of 118 unselected surgically treated patients with CRC. Sections from formalin fixed, paraffin embedded specimens were analysed for TLR2 and TLR4 expression by immunohistochemistry. Two independent assessors evaluated separately expression at the normal mucosa, at the invasive front and the bulk of the carcinoma, and in the lymph node metastases when present. Expression levels in different locations were compared and their associations with clinicopathological features including TNM-stage and the grade of the tumour and 5-year follow-up observations were analysed.RESULTS Normal colorectal epithelium showed a gradient of expression of both TLR2 and TLR4 with low levels in the crypt bases and high levels in the surface. In CRC, expression of both TLRs was present in all cases and in the major proportion of tumour cells. Compared to normal epithelium, TLR4 expression was significantly weaker but TLR2 expression stronger in carcinoma cells. Weak TLR4 expression in the invasive front was associated with distant metastases and worse cancerspecific survival at 5 years. In tumours of the proximal colon the cancer-specific survival at 5 years was 36.9% better with strong TLR4 expression as compared with those with weak expression(P = 0.044). In contrast, TLR2 expression levels were not associated with prognosis. Tumour cells in the lymph node metastases showed higher TLR4 expression and lower TLR2 expression than cells in primary tumours.CONCLUSION Tumour cells in CRC show downregulation of TLR4 and upregulation of TLR2. Low expression of TLR4 in the invasive front predicts poor prognosis and metastatic disease.
出处 《World Journal of Gastroenterology》 SCIE CAS 2017年第26期4831-4838,共8页 世界胃肠病学杂志(英文版)
基金 Supported by a grant from the Mary and Georg C Ehrnrooth Foundation,Finland
关键词 Colorectal Cancer Toll-like receptor 2 Toll-like receptor 4 INFLAMMATION PROGNOSIS Colorectal 癌症;像使用费的受体 2;像使用费的受体 4;发炎;预后
  • 相关文献

参考文献1

二级参考文献56

  • 1Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, RosenbergHM, Vernon SW, Cronin K, Edwards BK. The annual reportto the nation on the status of cancer, 1973-1997, with a specialsection on colorectal cancer. Cancer 2000; 88: 2398-2424 [PMID:10820364 DOI: 10.1002/(SICI)1097-0142(20000515)88:10<2398::AIDCNCR26>3.0.CO;2-I].
  • 2Simmonds PC. Palliative chemotherapy for advanced colorectalcancer: systematic review and meta-analysis. Colorectal CancerCollaborative Group. BMJ 2000; 321: 531-535 [PMID: 10968812DOI: 10.1136/bmj.321.7260.531].
  • 3Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survivalof patients with advanced colorectal cancer improves with theavailability of fluorouracil-leucovorin, irinotecan, and oxaliplatin inthe course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID:15051767 DOI: 10.1200/JCO.2004.11.037].
  • 4Saltz LB, Clarke S, Dz-Rubio E, Scheithauer W, Figer A, WongR, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, SirzF, Cassidy J. Bevacizumab in combination with oxaliplatin-basedchemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019[PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930].
  • 5Van Cutsem E, Kne CH, Hitre E, Zaluski J, Chang Chien CR,Makhson A, D'aens G, Pint T, Lim R, Bodoky G, Roh JK,Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J,Rougier P. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417[PMID: 19339720 DOI: 10.1056/NEJMoa0805019].
  • 6Chibaudel B, Tournigand C, Andr-T, de Gramont A. Therapeuticstrategy in unresectable metastatic colorectal cancer. Ther Adv MedOncol 2012; 4: 75-89 [PMID: 22423266 DOI: 10.1177/1758834011431592].
  • 7Sobin L, Gospodarowicz M, Wittekind C. International againstCancer. TNM classification of malignant tumors, 7th ed. New York:Wiley-Blackwell, 2009: 73-77.
  • 8Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, NishiguchiY, Sowa M. Combined analysis of p53 and vascular endothelialgrowth factor expression in colorectal carcinoma for determinationof tumor vascularity and liver metastasis. Int J Cancer 1997; 74:502-507 [PMID: 9355971 DOI: 10.1002/(SICI)1097-0215(19971021)74:5<502::AID-IJC4>3.0.CO;2-7].
  • 9Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, YamashitaY, Onoda N, Kato Y, Nitta A, Arimoto Y. Tumor angiogenesis as apredictor of recurrence in gastric carcinoma. J Clin Oncol 1995; 13:477-481 [PMID: 7531224].
  • 10Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis incolorectal cancer: prognostic and therapeutic implications. Am JClin Oncol 2006; 29: 408-417 [PMID: 16891872 DOI: 10.1097/01.coc.0000221317.56731.4e].

共引文献12

同被引文献29

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部